Oncobiologics, Inc. Series B Warrant
ONSIZ
ONSIZ was delisted on the 16th of May, 2018.
11 hedge funds and large institutions have $3.4M invested in Oncobiologics, Inc. Series B Warrant in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
270% more capital invested
Capital invested by funds: $918K → $3.4M (+$2.48M)
15% less funds holding
Funds holding: 13 → 11 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$357K |
| 2 |
PA
Perceptive Advisors
New York
|
+$141K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.12K |
| 4 |
Morgan Stanley
New York
|
+$2.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$14K |
| 2 |
Millennium Management
New York
|
-$1.12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $1.33M | +$357K | +489,728 | +112% |
|
|
PA
2
Perceptive Advisors
New York
| $787K | +$141K | +193,882 | +42% |
|
|
CAM
3
Cormorant Asset Management
Boston,
Massachusetts
| $500K | – | – | – |
|
|
ACA
4
Avoro Capital Advisors
New York
| $233K | – | – | – |
|
5
Marshall Wace
London,
United Kingdom
| $150K | – | – | – |
|
|
PC
6
PointState Capital
New York
| $120K | – | – | – |
|
|
ACP
7
Acuta Capital Partners
Redwood City,
California
| $97K | – | – | – |
|
|
JG
8
Jefferies Group
New York
| $79K | – | – | – |
|
|
9
Millennium Management
New York
| $52K | -$1.12K | -1,531 | -3% |
|
|
MIM
10
Monashee Investment Management
Boston,
Massachusetts
| $30K | – | – | – |
|
|
11
Morgan Stanley
New York
| $9K | +$2.28K | +3,120 | +54% |
|
|
12
UBS Group
Zurich,
Switzerland
| $7K | +$4.12K | +5,650 | +753% |
|
|
13
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$14K | -31,250 | Closed |
|
ONSIZ Hedge Fund Activity: Q3 2016 in Review
11 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Oncobiologics, Inc. Series B Warrant (ONSIZ) for Q3 2016, worth a combined $3.4M — up 270% from $918K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ONSIZ and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Sabby Management, adding an estimated $357K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $14K sold.
- 11 institutional investors held Oncobiologics, Inc. Series B Warrant (ONSIZ) as of Q3 2016, down from 13 in Q2 2016.
- Funds reported $3.4M of Oncobiologics, Inc. Series B Warrant stock for Q3 2016, up 270% quarter-over-quarter.
- 0 funds opened new Oncobiologics, Inc. Series B Warrant positions in Q3 2016 and 2 closed out, a net change of -2 holders.
- The largest Oncobiologics, Inc. Series B Warrant buyer in Q3 2016 was Sabby Management, an estimated $357K added.
- The largest Oncobiologics, Inc. Series B Warrant seller in Q3 2016 was Hudson Bay Capital Management, an estimated $14K sold.
Based on aggregated 13F filings for Q3 2016.